Literature DB >> 3866457

False-negative results in cervical cytologic studies.

J D Gay, L D Donaldson, J R Goellner.   

Abstract

The appropriate interval between cervical cytologic screening studies is a matter of considerable controversy, with a major consideration being the problem of false-negative results. To determine the rate of false-negative cervical cytologic results in our laboratory and to determine how these failures occur, tissue-proven cases of carcinoma in situ, invasive squamous-cell carcinoma, endocervical adenocarcinoma and lymphoid malignancy involving the cervix with negative Papanicolaou smears obtained within one year prior to the tissue diagnosis were reviewed. Over the four-year period from 1980 through 1983, 339 patients had tissue-proven cervical malignancies. Of these, 66 had false-negative Papanicolaou smears, representing a 20% overall false-negative rate. These false-negative smears were rescreened. For all types of cervical malignancy, the majority of errors were due to sampling. No malignancy was missed disproportionately by either cytotechnologists or cytopathologists. We plan to utilize these data for quality control purposes and for continued review of future performance.

Entities:  

Mesh:

Year:  1985        PMID: 3866457

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  14 in total

1.  Screening for cervical cancer. Canadian programmatic guidelines.

Authors:  J Parboosingh
Journal:  Can Fam Physician       Date:  1999-02       Impact factor: 3.275

2.  Fourier transform infrared (FTIR) spectral mapping of the cervical transformation zone, and dysplastic squamous epithelium.

Authors:  B R Wood; L Chiriboga; H Yee; M A Quinn; D McNaughton; M Diem
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

3.  Quality improvement in family practice. Program for Pap smears.

Authors:  P G Norton; P A Shaw; M A Murray
Journal:  Can Fam Physician       Date:  1997-03       Impact factor: 3.275

4.  Cytological early detection of cervical carcinoma: possibilities and limitations. Analysis of failures.

Authors:  G Möbius
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  The pap smear and cervical cancer screening.

Authors:  T J Elmslie
Journal:  Can Fam Physician       Date:  1987-01       Impact factor: 3.275

6.  Will New Human Papillomavirus Diagnostics Improve Cervical Cancer Control Efforts?

Authors:  Shalini L. Kulasingam; Laura A. Koutsky
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

Review 7.  A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening.

Authors:  Insiyyah Y Patanwala; Heidi M Bauer; Justin Miyamoto; Ina U Park; Megan J Huchko; Karen K Smith-McCune
Journal:  Am J Obstet Gynecol       Date:  2012-11-15       Impact factor: 8.661

Review 8.  Cervical premalignant lesions and their management.

Authors:  Faruk M Köse; Murat M Naki
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-06-01

9.  Liquid-based cytology for primary cervical cancer screening: a multi-centre study.

Authors:  J Monsonego; A Autillo-Touati; C Bergeron; R Dachez; J Liaras; J Saurel; L Zerat; P Chatelain; C Mottot
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

10.  Smear misclassification in a cervical cancer screening programme.

Authors:  E Lynge; E Arffmann; P Poll; P K Anderson
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.